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Abstract
Purpose The aim of this study was to develop a clinically ap-
plicable limited sampling strategy for ambulatory Caucasian
kidney transplant patients to estimate area under the curve in a
24-h period (AUC0–24) of prolonged-release tacrolimus.
Methods Twenty six kidney recipients, at least 6 months after
transplantation, receiving prolonged-release tacrolimus, were
enrolled. In each patient, seven blood samples were collected
during a period of 24 h by use of the validated dried blood spot
method. Best subset selection multiple linear regression was
performed to derive limited sampling strategy (LSS). The
equations were constrained to include a maximum of three
samples collected within 4 h after the intake to maintain clin-
ical applicability. To assess the predictive performance of
LSS, residuals for each patient were calculated based on
models fitted to a dataset where that patient was omitted.
Results The prediction formula for the AUC0–24 using the
time points 0, 2, and 4 h after ingestion (C0h-C2h-C4h) provid-
ed the highest correlation with the AUC0–24 (r
2=0.95):
AUC0–24=44.9+8.9×C0h+2.1×C2h+7.6×C4h. Measures for
bias and precision, i.e., median percentage prediction error
(MPPE) and median absolute prediction error (MAPE), were
0.4 and 4.8 %, respectively. For the same patients, the corre-
lation between C24h and AUC0–24 was worse (r
2=0.77) while
MPPE and MAPE were 6.2 and 7.2 %, respectively.
Conclusion In the outpatient department, a LSS using C0h-
C2h-C4h can be used for reliable estimation of the AUC0–24
of prolonged-release tacrolimus.
Keywords Exposure . Limited sampling strategy .
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Introduction
Tacrolimus is a usual component of the immunosuppressive
regimen after renal transplantation. While it was developed as
an oral twice-daily formulation, a prolonged-release once-dai-
ly formulation was launched a few years ago. The efficacy and
safety profile of prolonged-release tacrolimus are comparable
to that of the twice-daily formulation [3, 9]. Kuijpers et al.
demonstrated that the once-daily administration of tacrolimus
improves adherence, which might ultimately contribute to bet-
ter graft outcomes [11]. Moreover, intra patient variability in
exposure is somewhat lower with the prolonged-release for-
mulation [18].
Although the relationship between tacrolimus exposure
and clinical response has not yet been fully established, ther-
apeutic drug monitoring (TDM), i.e., individualization of the
dose based on concentration measurements, is indicated for
tacrolimus. TDM aims to improve the efficacy of tacrolimus,
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prevents overexposure and associated adverse effects, and de-
tects drug interactions or unexpected pharmacogenetic influ-
ences on exposure to this immunosuppressive drug [21]. In an
expert meeting, it was concluded that the area under the con-
centration versus time curve (AUC), which is calculated on
the basis of a full pharmacokinetic profile, is the best measure
of exposure to tacrolimus [21]. However, assessment of a full
pharmacokinetic profile requires the collection of many blood
samples and is therefore costly, time consuming, and uncom-
fortable, in particular for ambulatory patients. These draw-
backs hinder recording of the AUC in routine practice.
Trough levels are commonly used to estimate exposure since
they show a moderate to high correlation with AUC [2, 3, 6,
20, 23]. In spite of this moderate to high correlation, AUC can
vary up to twofold for the same trough level. For that reason,
concerns have been raised about the use of the trough level
[5].
A more reliable estimation of the total exposure can be
obtained by a limited sampling strategy (LSS). This means
sampling at limited or optimal sampling times, still allowing
for an accurate and precise estimation of the AUC [15, 19].
Clearly, a LSS also overcomes logistical and financial disad-
vantages of a full pharmacokinetic profile. However, an ap-
propriate LSS for ambulatory Caucasian renal transplant pa-
tients who use prolonged-release tacrolimus is not available.
Therefore, the aim of this study was to develop a clinically
applicable LSS to estimate the area under the curve in a 24-h
period (AUC0–24) of prolonged-release tacrolimus in them.
This would also allow us to assess the performance of the
trough level, as a single sample, to predict the AUC0–24 of
prolonged-release tacrolimus.
Patients and methods
Study design and population
We carried out a prospective pharmacokinetic study to assess
tacrolimus concentrations during a period of 24 h after inges-
tion of prolonged-release tacrolimus in the morning.
Adult renal transplant patients with a stable graft function
were eligible for enrolment if they used prolonged-release
tacrolimus (Advagraf®, Astellas Pharma) of which the dose
was not altered during the last visit to the outpatient clinic, and
the two most recently measured trough levels were within the
target range of 5–10 μg/L. Patients were excluded if they were
unable to perform the home-based dried blood spot measure-
ments of tacrolimus levels (see below) or if they had diarrhea
(more than three stools per day) during the preceding 14 days,
as we considered that diarrhea might affect the ratio between
AUC0–24 and trough levels [12].
The study was approved by the local ethics committee and
conducted in accordance with the 1964 Helsinki Declaration
and its later amendments. Informed consent was obtained
from all individual participants included in the study.
Measurements
Avalidated dried blood spot method for sampling and analysis
of tacrolimus was used, which allowed participants to take
their own blood samples at home [10]. Accuracy and intra-
and interassay precision were <15 and <7.5 %, respectively.
Using this method, capillary blood is obtained by a finger
prick with an automatic lancet by the patients themselves.
Subsequently, the first two drops of blood are applied to the
sampling paper to fill two 8-mm premarked circles for dupli-
cate sampling. After at least 10 min drying at room tempera-
ture, the samples are stored in a sealed plastic bag and sent by
regular post to the laboratory. Here, the disks from the blood
spot are punched out, extracted, and analyzed by a specific
high-performance liquid chromatography-tandem mass spec-
trometry (HPLC-MS/MS) method. Participants received thor-
ough training in using this method prior to performing the
pharmacokinetic measurements, and they could only be in-
cluded if their test blood sample passed the quality control.
Each pharmacokinetic profile started with measurement of
the whole blood tacrolimus concentration at 24 h after the
previous morning ingestion of prolonged-release tacrolimus
and after overnight fasting (C0). Subsequently, prolonged-
release tacrolimus was taken and blood samples were collect-
ed at 1, 2, 4, 8, 12, and 24 h after the ingestion. On the day of
the measurements, all participants took prolonged-release ta-
crolimus on an empty stomach and refrained from food intake
until 2 h after its ingestion since it has been reported that the
tacrolimus concentration profile can be influenced by meal
consumption [7]. Administration of prolonged-release tacroli-
mus on an empty stomach is also recommended in the product
information.
Pharmacokinetic parameters were assessed with
noncompartmental methods using WinNonLin version 5.0
(Pharsight Co version 5.0, Mountain View, CA). The AUC0–
24 was calculated by the linear-log trapezoidal rule. C0, C24,
the maximum blood concentration (Cmax), and time required
to reach it (Tmax) were directly read from the pharmacokinetic
curves. Elimination rate constant β was obtained by least
squares linear regression analysis on logarithmic concentra-
tions versus time post-dose, with the slope of the regression
line being -β/2.303. Apparent clearance (Cl/F where F is bio-
availability) was calculated by dividing dose by AUC0–24 and
apparent volume of distribution (Vd/F) was obtained by di-
viding Cl/F by β.
Statistical analysis
Loose concentrations and pharmacokinetic parameters were
described with a geometric mean and 95 % confidence
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interval. Tmax and daily tacrolimus dose were presented as
median and range. The other data were shown as median with
interquartile range. Correlations between numerical variables
were calculated using the non-parametric Spearman’s rank
correlation coefficient (rho).
We carried out best subset selection multiple linear re-
gression to derive limited sampling equations which pre-
dicted the AUC0–24. Models were constrained to include a
maximum of three samples collected within 4 h after the
intake to maintain clinical applicability for patients in the
outpatient department. We also developed models with a
maximum of three samples within 12 h after the intake
since some patients execute home-based measurements by
use of the dried blood spot technique. As they do not need
to stay in the outpatient department for the measurements,
the time span of the LSS is less relevant. We calculated
the average adjusted r square for all subsets containing
one, two, or three samples, and the model with the highest
average r square was chosen.
To assess the predictive performances of the models, we
calculated residuals for each patient based on models fitted to
a dataset where that patient was omitted (jackknife analysis)
[19]. Potential bias in the predictions was assessed by using
median percentage prediction error (MPPE). For this measure,
residuals were converted to percentages by dividing the resid-
uals by the predicted values. We consideredMPPE<5 % to be
acceptable. Imprecision was assessed using median absolute
percentage prediction error (MAPE) for which we accepted a
percentage limit of <10 %. These strict criteria for predictive
performance were chosen considering the narrow therapeutic
index of tacrolimus, for which small changes in total exposure
could be clinically relevant. This is also reflected in altered
European guidelines for drug formulation bio-equivalence
studies, specifying that for narrow therapeutic index drugs
the acceptance interval for AUC can be tightened to 90.0–
111.1 % [1]. Niioka et al. recently used the same criteria for
MPPE and MAPE to evaluate their LSS for prolonged-release
tacrolimus in Japanese renal transplant recipients [13].
All statistical analyses were performed with SPSS for
Windows version 20.0 (SPSS Inc, Chicago, IL) and R version
2.15.2. P values of below 0.05 were considered significant.
Results
Of the thirty patients who were recruited for the study, 26
patients completed a full pharmacokinetic profile. Four exclu-
sions were due to insufficient quality of the blood spots (n=1),
and giving up informed consent (n=3). All 26 participants had
an isolated kidney transplantation and were of Caucasian an-
cestry. Other patient characteristics are shown in Table 1.
Themedian daily dose of prolonged-release tacrolimuswas
4.0 mg (range 1.5–10.0). The geometric mean C0 and 24-h
post-dose trough level (C24) were 7.7 μg/L (95 % confidence
interval 7.0–8.5) and 8.3 μg/L (7.5–9.1), respectively. The
geometric mean AUC0–24 of tacrolimus was 288 μg h/L
(262–317). The mean ratio of AUC0–24 and C24 was 34.8
(33.2–36.5). The pharmacokinetics of prolonged-release ta-
crolimus are summarized in Supplementary Figure 1 and
Supplementary Table 1.
Various sampling time points and combinations of sam-
pling time points were used to construct a regression
model for the prediction of the AUC0–24. Relatively high
adjusted r2 values, approaching 0.90, could already be
reached with inclusion of only one sampling time, but r2
increased with the inclusion of two or three sampling
times. The best performing limited sampling strategies
for ambulatory patients in the outpatient department,
based on one, two, or three time points within 4 h post-
dose, are shown in Table 2A. Sampling at 0, 2, and 4 h
post-dose provided the best prediction of AUC0–24. The
adjusted r2 was 0.95 and MPPE and MAPE, measures for
bias and precision of the prediction formulas, were 0.4
and 4.8 %, respectively. For patients who performed
home-based measurements (sampling allowed up to 12 h
post-dose), an equation with sampling times at 2, 8, and
12 h post-dose revealed the best results. The adjusted r2
was 0.98 and MPPE and MAPE were 0.4 and 2.8 %,
respectively (Table 2B).
The commonly used trough level (C24) to predict exposure
to prolonged-release tacrolimus provided an adjusted r2 of
0.77 with AUC0–24. MPPE and MAPE of C24 were 6.2 and
7.2 %, respectively. The strongest correlation between a single
measurement and AUC0–24 was found for C8 (adjusted r
2=
0.89) while MPPE and MAPE in this case were 1.2 and 5.2 %
(Table 2B).
No relevant effect of hematocrit and co-administration of
steroids and calcium channel blockers (CCBs) on adjusted r2
and predictive performances of the prediction formulas with
sampling at 0, 2, and 4 h or at 2, 8, and 12 h post-dose was
apparent (Supplementary Table 2).
Table 1 Patient characteristics (n=26)
Male (%) 69
Caucasian (%) 100
Age (years) 43.9 (36.1–57.6)
Weight (kg) 78.4 (72.6–86.1)
Time after transplantation (years) 5.4 (2.3–7.1)
eGFR (mL/min/1.73 m2) 51.5 (40.8–59.3)
Hematocrit 0.39 (0.36–0.41)
Albumin (g/L) 39.5 (36.0–41.0)
Use of calcium channel blockers (%) 58
Use of steroids (%) 77
Data are shown as median with interquartile range
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Discussion
In this study, we developed equations to estimate AUC0–24 of
prolonged-release tacrolimus which are clinically applicable
for ambulatory Caucasian renal transplant patients. These
strategies enclose up to three sampling time points and pro-
vide an accurate and precise estimation of the AUC0–24.
In daily clinical practice, the trough level (C24) of
prolonged-release tacrolimus is commonly used to establish
whether exposure is adequate. The dose of prolonged-release
tacrolimus is adjusted if C24 is outside the defined target range.
According to most studies, there is a moderate to high corre-
lation between trough level and exposure to prolonged-release
tacrolimus [2, 3, 6, 20, 23]. In fact, r2 of 0.77 in the current
study confirms this correlation. However, concerns have been
raised that this degree of correlation is not sufficient since
correlation is not a good measure for predictive performance
[5]. It should be better evaluated in terms of bias and precision,
which are expressed as MPPE and MAPE, respectively [16,
19]. Criteria for MPPE andMAPE are somewhat arbitrary and
maximum values of 15–20 % have been suggested before
[19]. However, these limits are not strict enough for a drug
with a narrow therapeutic index. In agreement with Niioka
et al., we chose to use 5 and 10 % as cut-off values for accept-
able MPPE and MAPE [13]. According to these criteria, the
prediction of AUC0–24 based on trough levels was biased (yet
precise). Interestingly, Scholten et al. showed that overexpo-
sure to tacrolimus in patients using the regular formulation
was less frequent when dosing was based on AUC measure-
ments as compared to trough levels only [15]. Although this
has not been demonstrated for the prolonged-release formula-
tion of tacrolimus, it is likely that the same holds true here
since the correlation between trough levels and AUC are about
the same for either formulation.
The two main approaches for developing LSS are multiple
linear regression and Bayesian analysis. They are equally val-
id but have different advantages and disadvantages [19]. We
preferred multiple regression analysis as it is relatively simple
to develop, to use, and to incorporate in clinical practice. The
regression analyses are conceptually clear, and this approach
is not dependent on knowledge or assumptions on the phar-
macokinetics of the drug and the choice of a specific pharma-
cokinetic model. Once equations are obtained, AUC values
can be estimated by straightforward calculations that can even
be done manually. Disadvantages are that only limited devia-
tion from target sampling times is allowed and that the LSS is
only applicable for patients with similar characteristics as for
whom the strategy was developed. Our LSS is therefore only
applicable in Caucasian patients who take prolonged-release
tacrolimus on an empty stomach as recommended in the prod-
uct information. The Bayesian forecasting method uses pop-
ulation pharmacokinetic data, drug dosing information, and
measured concentrations to estimate pharmacokinetic param-
eters of the individual patient. Advantages of Bayesian fore-
casting combined with limited sampling are flexibility with
sampling times, and simultaneous prediction of several phar-
macokinetic parameters. Moreover, the LSS can continuously
be updated by incorporating new data into the population data
set. However, the Bayesian strategy also requires expertise
with specific software and a choice for a pharmacokinetic
model of the drug that affects the predictive performance of
the LSS. Furthermore, users need extensive training in oper-
ating the programs and interpreting the results, and Bayesian
analysis demands for rather extensive data entry which may
not be feasible in daily clinical practice.
In our study, we did not prospectively validate our limited
sampling formulas. Alternatively, we computed residuals for
every patient in a model which fitted to a dataset where that
patient was omitted. This analysis is a useful and appropriate
approach if the sample size is small [19].
Differences in pharmacokinetics of tacrolimus are partly
explained by genetic polymorphisms of CYP3A5 [17].
Moreover, co-medication as steroids and CCBs affect the
pharmacokinetics of this drug. Therefore, it is important to
Table 2 Best performing one, two and three sampling strategies for estimation of AUC0–24 of prolonged-release tacrolimus for (A) sampling up to 4 h
allowed, and (B) sampling up to 12 h allowed
Sampling times Equation Adjusted r2 MPPE % MAPE %
A
T4 AUC0–24=107.6+10.6×C4 0.89 −0.25 5.73
T0, T4 AUC0–24=57.5+10.1×C0+8.9×C4 0.93 0.45 5.27
T0, T2, T4 AUC0–24=44.9+8.9×C0+2.1×C2+7.6×C4 0.95 0.38 4.80
B
T8 AUC0–24=37.6+20.6×C8 0.89 1.23 5.21
T8, T12 AUC0–24=−8.8+11.8×C8+14.2×C12 0.96 −0.28 4.71
T2, T8, T12 AUC0–24=−12.8+2.1×C2+9.7×C8+12.7×C12 0.98 −0.38 2.82
The equations were developed for Caucasian kidney transplant recipients who took prolonged-release tacrolimus on an empty stomach
MPPE median percentage prediction error, MAPE median absolute prediction error, AUC0–24 area under the curve in a 24-h period
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determine whether bias and precision in the several prediction
formulas are affected by CYP3A5 polymorphism or use of co-
medication. We showed that CYP3A5 polymorphisms and
co-medication did not significantly influence the perfor-
mances of the prediction formulas. Niioka et al. previously
showed that in their developed LSS, the effect of CYP3A5
polymorphism was also irrelevant [13].
One LSS using multiple linear regression and three limited
sampling strategies by use of the Bayesian forecasting method
have currently been published for prolonged-release tacroli-
mus in adult renal transplant patients [5, 13, 14, 24]. The LSS
for prolonged-release tacrolimus which used multiple regres-
sion was described by Niioka et al. [13]. Their LSS was de-
veloped in Japanese patients while our LSS is applicable for
Caucasian patients. Moreover, they used the chemilumines-
cence magnetic microparticle immunoassay on the
Architect-i1000 system (Abbott Laboratories; Abbott Park,
IL) for bio-analysis of tacrolimus, whereas we used the highly
specific HPLC-MS/MS method which does not measure
cross-reacting inactive tacrolimus metabolites [4, 8, 22]. For
limited sampling during a period of 4 h, they also found 0, 2,
and 4 h post-dose as optimal sampling strategy. However, the
correlation between predicted and observed AUC0–24 ap-
peared higher (r2 0.95 versus 0.85) and precision appeared
better (MAPE 4.8 versus 9.8 %) with our formula. Their
LSS for home-based measurements contained 3 sampling
time points at 0, 3, and 12 h post-dose, compared to 2, 8,
and 12 h post-dose in our study. The correlation and predictive
performances appeared comparable. The limited sampling
strategies using the Bayesian forecasting method all enclosed
sampling at 0, 1, and 3 h post-dose [5, 14, 24].
For this study, we used the innovative Bdried blood spot^
technique which has proven to be very reliable for determin-
ing tacrolimus levels [10]. This technique requires careful
training of the patients involved, but then obviates the need
for hospital visits, phlebotomies, and clinical research facili-
ties. Therefore, this technique seems very suitable for obser-
vational pharmacokinetic studies in a home-based, day-to-day
clinical setting [18]. In routine clinical care, the dried blood
spot technique can also be used for a selected group of patients
who can be taught well and are able to execute it. Therefore,
we also developed prediction formulas in which the time span
of LSS is less relevant.
Finally, the AUC of tacrolimus is considered to be a better
measure for exposure than the trough level [21]. However, it
has not been proven that AUC-based TDM resulted in a better
graft or patient survival than trough level-based TDM [21].
Moreover, the target AUC of tacrolimus for patients who are
more than 6 months after renal transplantation has to be
established. Additional prospective trials with large patient
numbers would therefore be needed to assess the effects of
using AUC versus trough level on outcome and to determine
the target AUC. We would especially be interested in studies
with patients for whom a better estimation of the exposure to
tacrolimus is critical, like highly immunized patients or pa-
tients with calcineurin inhibitor nephrotoxicity.
In conclusion, a LSS using samples collected before the
intake and at 2 and 4 h post-dose can be applied for a very
accurate and precise estimation of the AUC0–24 of prolonged-
release tacrolimus in ambulatory renal transplant patients. A
LSS with samples obtained before the intake and at 3 and 12 h
also showed a good predictive performance but it seems only
suitable for patients who can execute the dried blood spot
measurement at home.
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